Bioelectronics Corp (BIEL)

[3331]

The Math Behind the 3,700 Pharmacy Store Rollout
Everyone is tracking Electrome’s active VA deployments (with insurance coverage and the and higher profit margin RecoveryRX), but the massive catalyst hitting the ledger in late 2026 is the 3,700-store national pharmacy retail rollout. In medical device plays, retail rollouts follow a specific revenue pattern: Pipeline Fill - Restock Velocity. Because Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside, the numbers scale rapidly. Based on a fixed OEM wholesale price of $15.00 per module to BIEL, here is how the math breaks down:

Phase 1: The "Pipeline Fill" (Late 2026)
Before a single consumer buys a product, pharmacies must stock their shelves. This triggers immediate bulk hardware orders for BIEL to fill the retail pipeline.

Initial Shelf Stocking: Estimated 5 to 10 units per store to secure initial shelf presence and display inventory.
Total Initial Hardware Volume: 18,500 to 37,000 upfront units required across all 3,700 locations.
Fixed OEM Price to BIEL: $15.00 per module.
Projected Late-2026 Revenue Catalyst: $277,500 to $555,000 in immediate, upfront OEM hardware invoices.

Phase 2: Sustained Restock Velocity (Full-Year 2027)
The real inflection point happens in 2027 as consumer adoption drives recurring, predictable reorders to keep shelves stocked.
Conservative Turn Rate: Estimated sales of just 2 to 4 units per store, per month.
Annualized Volume Required: 88,800 to 177,600 total units flowing through the network.
Fixed OEM Price to BIEL: $15.00 per module.
Projected 2027 Revenue Run-Rate: $1.33M to $2.66M from the retail channel alone.

The Razor-Blade Advantage: Because Electrome’s platform utilizes BIEL’s core tech (ActiPatch/RecoveryRx), BIEL captures revenue on both the initial kit buy and the high-margin replacement modules consumers purchase later.

Conclusion
Stacked Revenue Streams: This $1.33M–$2.66M retail runway sits on top of the $0.75M–$2.25M baseline revenue BIEL is already modeling for early 2026 from active VA deployments, pilot clinics, and clinical onboarding.

De-Risked Growth: BIEL isn't paying for the retail marketing, distribution logistics, or shelf-space slotting fees—Electrome is. BIEL simply collects clean OEM hardware revenue on every single unit shipped.

Bottom Line: The revenue clock hasn't just started; it is accelerating. Late 2026 establishes the retail footprint, and 2027 is positioned to be a major breakout year for BIEL’s balance sheet.

BIEL PPS HITS COPPER THIS YEAR, SILVER IN 2027, $1 in 2028
Based on the Electrome (currently US/Canada) partnership alone, and not counting Haleon as a possible future global partner. The momentum has already started, as demonstrated by the recent 400% PPS surge, outperforming 99.9% of all stocks.

BIEL begins generating revenue the moment Electrome ships commercial PAINKILLER™ units — which is already underway in 2026. The revenue clock has started. The first meaningful revenue shows up in 2026, with scale accelerating into 2027.

1. Electrome’s PAINKILLER™ Rollout = Immediate OEM Orders for BIEL
Electrome’s platform requires BIEL hardware in every kit:
ActiPatch
RecoveryRx
Veterinary PEMF modules

Electrome cannot ship a single PAINKILLER™ unit without purchasing BIEL hardware first.

Electrome has already:
begun VA deployments
begun clinical onboarding
begun pilot rollouts
secured Capital Factory backing
secured celebrity investor validation

Every one of these deployments requires hardware. Hardware shipments = BIEL invoices Electrome. This is already happening in 2026.

2. The VA Rollout Is Active — Not Theoretical
Electrome is already operating inside the U.S. Department of Veterans Affairs, the largest healthcare system in the country.

VA deployments = hardware shipments = BIEL revenue. This is not a future catalyst. It is a current revenue stream.

3. Electrome’s 2026 Commercial Launch = First Meaningful Revenue Wave
Electrome’s PAINKILLER™ platform launches in phases:

Phase 1 (2026): Early Commercial Rollout
VA deployments
Pilot clinics
Early adopter programs
Initial retail/consumer onboarding

This phase alone is modeled at $0.75M–$2.25M in OEM hardware revenue for BIEL. This is 2026 revenue, not 2027.

4. The 3,700-Store Retail Rollout Begins in 2026
Electrome’s retail strategy includes:
national pharmacy chains
consumer health retail
global distribution partners
Retail rollout = bulk hardware orders = BIEL revenue

This begins late 2026 and accelerates into 2027.

5. Electrome’s Rise Is BIEL’s Revenue Inflection Point
Electrome is executing the same model that made Medvi explode — but with:
FDA-cleared hardware
global distribution
VA deployments
celebrity investor validation
international adoption
a massive unmet need (chronic pain)
a platform that scales like software

This is why 2026 is the first real revenue year, and 2027 is the scale year.

6. Summary Timeline
Q1–Q2 2026
VA deployments begin - BIEL revenue starts

Q2–Q3 2026
PAINKILLER™ commercial rollout - OEM revenue ramps

Q3–Q4 2026
Retail onboarding + global distribution - bulk orders begin

2027
Full-scale OEM revenue across human, veterinary, and consumer health - multi-million-dollar annual run rate

Bottom Line:
BIEL is already generating revenue from Electrome in 2026.
The first meaningful wave is this year, and exponential scale begins in 2027.

PROFITABILITY IS WITHIN REACH
BIEL has already demonstrated how close it is - Q3 2021 profit:
$22,381 profit on $414,700 revenue (including $100K COVID relief).
With an ultra-lean model, sustained profitability is imminent.
Because BIEL’s operating costs are near zero, the revenue-to-profit conversion is extreme (estimate every $3M in revenue generates $2.5M profit).

THE BIEL QUANTUM LEAP
If BIEL delivers $2.5M in net profit, it could command a $2.5B market cap — equivalent to $0.10 PPS at a P/E of 1000. P/E ratios above 1,000 are common for early hypergrowth disruptors:
Amazon
Tesla
Salesforce
Zoom
Synaptics

BIEL fits this profile once profitability aligns with the Electrome narrative. And don’t forget: $40M tax-loss carryforward accelerates net profitability.

PPS PROJECTIONS
Key assumption: Every $3M in revenue = $2.5M profit = $0.01 PPS, P/E = 1000.

.001 — Technical breakout (Blue Sky Breakout)
.01 — Cash-flow positive - achieved with $1 - 1.5M rev in 2026, (double/triple 2025 rev)
.10 — $2.5M profit - achieved with 3M+ revenue (2027, 2x/3x 2026)
$1.00 — After debt payoff + stock buyback (2028)

This timeline is based on the Electrome partnership only, and could be accelerated (cut in half) if BIEL / Electrome announce a global contract with Haleon! And don't forget the $500k revenue generated in 2025 (wherever that came from), Taiwan, etc.